$GILD Recent Headlines Gilead's high pricing of Sovaldi

New Post Public Reply Private Reply Replies (0) Message Board

Jul 14, 2014 at 11:07 AM

$GILD Recent Headlines

Gilead's high pricing of Sovaldi draws inquiry from Senate committee 1:36 p.m. July 11, 2014 - blogs.marketwatch.com
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
S&P 500, Nasdaq retest major support 12:12 p.m. July 8, 2014 - Michael Ashbaugh
S&P 500, Nasdaq retest major support 11:57 a.m. July 8, 2014 - Michael Ashbaugh
Growth stocks are doing most bullish thing they can 3:23 p.m. July 1, 2014 - The Trading Deck
Robo-advisors, Syrian strikes and the stock-market shift they signal 6:45 a.m. June 25, 2014 - blogs.marketwatch.com
Health-care inflation heating back up 10:24 a.m. June 24, 2014 - blogs.marketwatch.com
Medtronic’s real problem is innovation, not taxation 6:45 a.m. June 19, 2014 - Tim Mullaney
Rival to Gilead's pricey Sovaldi expected to hit market later this year 7:28 a.m. June 18, 2014 - blogs.marketwatch.com
Tyson falls on Hillshire deal; Apple gains post-split 3:49 p.m. June 9, 2014 - Saumya Vaishampayan
Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com

3 Biotech Stocks That Belong in Your Portfolio 4:45 a.m. Today - InvestorPlace.com
Cuomo's Plan for HIV Drug Draws Critics 9:57 p.m. July 13, 2014 - The Wall Street Journal Interactive Edition
Biogen's Profit Rolls Amid Recent Drug Launches 6:14 p.m. July 11, 2014 - Investors Business Daily
Senators Investigating Hepatitis C Drug Pricing 5:45 p.m. July 11, 2014 - The Wall Street Journal Interactive Edition
Senators Ask Gilead To Explain Sovaldi Pricing 10:35 a.m. July 11, 2014 - Investors Business Daily
Senators ask Gilead for Sovaldi pricing info 10:09 a.m. July 11, 2014 - Seeking Alpha
Trade-Ideas: Gilead (GILD) Is Today's New Lifetime High Stock 9:46 a.m. July 11, 2014 - TheStreet.com
Stocks Hitting 52-Week Highs 9:13 a.m. July 11, 2014 - benzinga.com
7 Most Heavily Shorted Nasdaq Stocks 8:43 a.m. July 11, 2014 - 247WallSt.com
J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views 3:31 p.m. July 10, 2014 - benzinga.com
My High Share Buyback And Dividend Growth Portfolio 2nd Quarter 2014 Update 12:05 p.m. July 10, 2014 - Seeking Alpha
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014 11:54 a.m. July 10, 2014 - TheStreet.com
Gilead Sciences Can Hit Par By The End Of The Year 11:35 a.m. July 10, 2014 - Seeking Alpha
A Pre-Earnings Update On Gilead 10:59 a.m. July 10, 2014 - Seeking Alpha
Gilead Sciences: Cause For Concern? 10:25 a.m. July 10, 2014 - Seeking Alpha
Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) 6:27 a.m. July 10, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM 6:00 a.m. July 10, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains 7:53 p.m. July 9, 2014 - TheStreet.com
3 Drugs Stocks Driving The Industry Higher 1:03 p.m. July 9, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – SGEN GILD TEVA IRWD 8:30 a.m. July 9, 2014 - InvestorPlace.com

Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 3:30 p.m. June 13, 2014 - PR Newswire - PRF
Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver 9:31 a.m. June 13, 2014 - PR Newswire - PRF
Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert 6:15 a.m. June 11, 2014 - Marketwire
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10 5:00 p.m. June 9, 2014 - BusinessWire - BZX
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. June 3, 2014 - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JumpCloud Tackles Compliance in the AI Era

Compliance in a Changing Tech Landscape JumpCloud's stepping up in this brave new world riddled with tech and AI agents. They've got fresh platform features in their arsenal that'll keep organizations audit-ready day in and day out. Now, if you think compliance is just for the accountants to fret over, think again. In the agentic era, these advanced marvels—AI agents...

Doximity Lawsuit: What Investors Need to Know Now

Lawsuit Clouds Hang Over Doximity The courtroom isn't typically where you find stocks making headlines, but Doximity's recent plunge isn't just a market hiccup. After a rough patch, an alleged misstep lands them squarely under the legal microscope, and investors have questions. Tracing Doximity's Rocky Financial Reports First, let's rewind to November last year. Doximity...

Clip Expands Horizons with Pulpos Acquisition, New Board Member

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Grupo Simec 2026 Nine-Month Financial Surge Spells Change

Sharp Climb in Net Income Sparks Interest Buckle up, folks. Grupo Simec's nine-month results for 2026 are a mixed bag of surprises and steady flows. Let’s break it down: the net income skyrocketed by a whopping 428% compared to the same period last year—jumping from Ps. 763 million to Ps. 4,028 million. That's a solid leap, and it’s largely due to turning a hefty...

Aktia Bank: Steady Ratings, Focused Expansion in Europe

Aktia's Ratings Get a Boost In the world of financial minutiae, it was S&P Global Ratings that took the stage, buzzing about Aktia Bank Plc. The bank just had its ratings held steady with an outlook lift from negative to stable. That's like someone throwing you a life jacket when you're treading water; significant if you're trying to stay afloat, not so much if you've got...

Covalent's Bet on AML Analytics: A Defense Revolution

The Big Play: AI Meets Financial Defense You know when a private equity firm swoops in, it's like the cavalry arriving. Covalent Equity Partners just did that for AML Analytics, or AMLA for short. A payday for them, sure, but it's more about amplifying AMLA's already hefty punch against financial crime, using AI to boot. Now, if AI's mentioned, you know someone's getting...

Ping An Shows Resilient Growth Amid Economic Pressure

Unpacking Ping An's Steady Climb Amid Tumult A few eyebrows might have raised when Ping An Insurance unveiled its nine-month report for 2026. Despite economic turbulence in China—courtesy of a gnarly global scene—the numbers were anything but rattled. Operating profit rose 8.3% year over year to a beefy RMB125,905 million. The equity pool swelled by 4.4% as of...

A.O. Smith Sells 81% of China Arm to CPE: Key Takeaways

When a major player like A.O. Smith decides to offload a piece of its business, folks tend to sit up and pay attention. This isn't just some run-of-the-mill shuffling. A.O. Smith has inked a deal with CPE to hand over an 81% stake in its China business. What does this transaction bring to the table and who stands to gain? Broken Down for the Curious Investor The numbers...

Chemours Faces Class Action over Misleading Guidance

Legal Storm Brewing for Chemours Investors Seems like The Chemours Company, trading under NYSE:CC, is in some legal hot water right now. With the calendar quickly flipping towards December 7, investors are fronted with a crucial choice: step up to stake their claim as lead plaintiff in a securities fraud class action lawsuit, or watch from the sidelines. The Allegations...

North Island Credit Union Eases Student Access to Banking

Breaking Down Barriers with Student Banking Services Stumble into any financial setup these days, and you'll hear the same refrain: young people need more access to banking. North Island Credit Union seems to have taken that idea to heart, landing a national Bank On certification for their Student Checking account. It ain't just any badge; it's the mark of reliability,...